These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24048298)

  • 1. Fraudulent data: an apology and the fate of angiotensin receptor blockers.
    Bangalore S; Messerli FH
    BMJ; 2013 Sep; 347():f5549. PubMed ID: 24048298
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.
    Bangalore S; Kumar S; Wetterslev J; Messerli FH
    BMJ; 2011 Apr; 342():d2234. PubMed ID: 21521728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Ravipati G; Aronow WS; Ahn C; Alappat RM; McClung JA; Weiss MB
    Am J Ther; 2009; 16(1):2-4. PubMed ID: 19114876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CHARM].
    Momomura S
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
    Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
    Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blockers and cardiovascular outcomes.
    Hobbs FD
    BMJ; 2011 Apr; 342():d2193. PubMed ID: 21527455
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction.
    Messerli FH; Bangalore S
    Circulation; 2017 May; 135(22):2085-2087. PubMed ID: 28559492
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.
    Beavers CJ; Dunn SP; Macaulay TE
    Ann Pharmacother; 2011 Apr; 45(4):520-4. PubMed ID: 21427294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
    McAlister FA;
    Eur Heart J; 2012 Feb; 33(4):505-14. PubMed ID: 22041554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical trials on protective efficacy of antihypertensive agents for organ damage due to diabetes mellitus complicated with hypertension].
    Higashiura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():623-7. PubMed ID: 15171446
    [No Abstract]   [Full Text] [Related]  

  • 11. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
    Yamaguchi K; Sata M
    Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials.
    Song HF; Wang S; Li HW
    Chin Med J (Engl); 2012 May; 125(10):1804-10. PubMed ID: 22800904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of ARB on prevention of atherosclerosis].
    Aoyama T; Minatoguchi S
    Nihon Rinsho; 2011 Jan; 69(1):92-9. PubMed ID: 21226267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.
    Flaa A; Aksnes TA; Strand A; Kjeldsen SE
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Organ protection by angiotensin II receptor blockers].
    Kumagai H; Onami T; Takimoto C; Iigaya K; Saruta T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():569-73. PubMed ID: 15171437
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
    Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
    Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin receptor blockers in myocardial infarction and ARB-MI paradox.
    Sharma AK; Wardhan H
    Indian Heart J; 2011; 63(1):79-83. PubMed ID: 23189869
    [No Abstract]   [Full Text] [Related]  

  • 19. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M
    QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.